Table 3.
Distribution of demographic and SLE patient characteristics according to side effects due to SARS-CoV-2 vaccination.
| Side Effects after First or Second Shot (n = 119) |
No Side Effects after First or Second Shot (n = 333) |
p-Value (<0.05) | |
|---|---|---|---|
| Age, years, median (IQR) | 46 (33.5–54) | 48 (35.75–57) | 0.1817 |
| Disease duration, months, median (IQR) | 138 (76–262.5) | 126 (73–193) | 0.3016 |
| Musculoskeletal involvement, % (n) | 84.9 (101) | 84.4 (281) | 1.00 |
| Mucocutaneus involvement, % (n) | 71.4 (85) | 62.8 (205) | 0.09403 |
| Renal involvement, % (n) | 42.0 (50) | 52.3 (174) | 0.06917 |
| NPSLE, % (n) | 13.4 (16) | 9 (30) | 0.2151 |
| Cardiopulmonary involvement, % (n) | 22.7 (27) | 19.8 (66) | 0.5109 |
| Haematological involvement, % (n) | 32.8 (39) | 33 (110) | 1.00 |
| Constitutional symptoms, % (n) | 48.7 (58) | 30 (100) | 0.000325 * |
| Gastrointestinal involvement, % (n) | 4.2 (5) | 3.3 (11) | 0.7726 |
| Ophthalmic involvement, % (n) | 0.8 (1) | 3.3 (11) | 0.1973 |
| Secondary anti-phospholipid syndrome, % (n) | 10.9 (13) | 10.5 (35) | 0.8641 |
| Anti-phospholipid antibodies positivity, % (n) | 26.2 (31) | 33.6 (112) | 0.1366 |
| Anti-dsDNA positivity, % (n) | 30.7 (35) | 27.4 (88) | 0.5453 |
| Anti-Sm positivity, % (n) | 12.6 (15) | 9.9 (33) | 0.4881 |
| Low complement (C3 and/or C4), % (n) | 37.8 (45) | 34.2 (114) | 0.5033 |
| ESR, mm/h, median (IQR) | 14 (7.25–19.75) | 13 (7–22) | 0.7303 |
| CRP, mg/dL, median (IQR) | 0.5 (0.1–0.5) | 0.5 (0.3–0.6) | 0.3122 |
| Presence of urinary abnormalities, % (n) | 9.2 (11) | 21.9 (73) | 0.002311 |
| Moderate or high DAS before vaccine, % (n) | 16 (19) | 9.3 (31) | 0.06011 |
| No therapy before vaccine, % (n) | 0 (0) | 3.6 (12) | 0.0419 * |
| At least 1 immunosuppressant #, % (n) | 63 (75) | 46.8 (156) | 0.002751 * |
| Mycophenolate, % (n) | 31.9 (38) | 23.1 (77) | 0.06606 |
| Methotrexate, % (n) | 5.9 (7) | 6.6 (22) | 1.00 |
| Belimumab, % (n) | 21.8 (26) | 13.5 (45) | 0.03956 * |
| Rituximab ever, % (n) | 11.8 (14) | 13.5 (45) | 0.7515 |
| Prednisone therapy, % (n) | 74.8 (89) | 70 (233) | 0.3468 |
* p-Value < 0.05. # Azatioprine, mycophenolate, belimumab, cyclophosphamide, leflunomide, adalimumab, rituximab, tocilizumab, tacrolimus. IQR: interquartile range. ESR: erythrocyte sedimentation rate. CRP: C-reactive protein. NPSLE: neuropsychiatric involvement in systemic lupus erythematosus. DAS: disease activity score.